2-氨基-4-(4-氟苯基)噻唑-5-甲腈 | 952753-59-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氨基-4-(4-氟苯基)噻唑-5-甲腈
• 英文名称: 2-amino-4-(4-fluorophenyl)thiazole-5-carbonitrile
• 英文别名: 2-Amino-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile；2-amino-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile
• CAS: 952753-59-2
• 化学式: C₁₀H₆FN₃S
• 分子量: 219.242
• InChiKey: BYCWHBXYLJAAEH-UHFFFAOYSA-N

物化性质

• 沸点：
  453.2±35.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-氨基-4-(4-氟苯基)噻唑-5-甲腈 在 三乙基硅烷 、 亚硝酸特丁酯 、 copper(II) choride dihydrate 、 sodium hydride 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 、 mineral oil 为溶剂， 反应 12.5h， 生成 2-((5-bromo-2-ethyl-7-methylbenzofuran-3-yl)(methyl)amino)-4-(4-fluorophenyl) thiazole-5-carbonitrile
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  本发明涉及一种杂环化合物及其应用和包含该化合物的药物组合物。本发明提供了一种由式I表示的杂环化合物或其药用可接受盐。该化合物具有新颖的结构，并且对自动税脂酶（ATX）具有良好的抑制活性。

  公开号：

  US20200369676A1
• 作为产物：
  描述：

  对氟苯甲酸乙酯 在 碘 、 sodium hydride 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 4.0h， 生成 2-氨基-4-(4-氟苯基)噻唑-5-甲腈
  参考文献：
  名称：

  Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects

  摘要：

  ATX was capable of catalyzing the hydrolysis of LPC to the lipid mediator LPA which attracted considerable attention on the development of potent ATX inhibitors. Herein, driven by the HTS product indolebased lead 1, a hybridization strategy was utilized to construct the trifluoroacetyl hydrazone moiety through assembling the phenyl thiazole fragment to the indole skeleton of lead 1. After a systematic structure guided optimization, by cycling the phenyl thiazole to the compacted benzothiazole or decreasing the lipophilicity, two promising ATX inhibitors (9j and 25a) were identified with IC50 values of 2.1 nM and 19.0 nM, respectively. All compounds were tested a panel of cancer cell lines and a preliminary affinity on breast cancer cell lines (SI > 16.5) were observed which shed a light on their potential application of breast cancer relevant cases. Through a dedicated docking study, the intramolecular pseudo-ring within the trifluoroacetylhydrazone moiety played a significant role in constraining the binding poses of 9j and 25a. Finally, a binding free energy calculation was conducted to examine the contribution of different interactions in binding affinity. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112456

文献信息

• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2014202458A1

  公开（公告）日：2014-12-24

  The present invention discloses compounds according to Formula I: Wherein R 1a, R 1b, R 2, R 4, R5, R 6, R 7, R 8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases,proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

  本发明公开了根据式I的化合物：其中R 1a、R 1b、R 2、R 4、R5、R 6、R 7、R 8、W、X、Y、Z、Cy和下标a如本文所定义。本发明涉及抑制自体脂肪酶（NPP2或ENPP2）的化合物，其制备方法，包含其的药物组合物，以及使用该化合物进行预防和/或治疗涉及纤维化疾病、增殖性疾病、炎症性疾病、自身免疫疾病、呼吸系统疾病、心血管疾病、神经退行性疾病、皮肤病和/或与异常血管生成相关疾病的方法。
• [EN] COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT DESTINÉS À TRAITER LES TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2014139882A1

  公开（公告）日：2014-09-18

  The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseasesby administering the compound of the invention.

  本发明公开了根据式I的化合物：其中R1a、R1b、R2、R4、R5、R6a、R6b、R7、R8、W、X、Cy和下标a如本文所定义。本发明涉及抑制自体脂肪酶（NPP2或ENPP2）的化合物，其制备方法，包含其的药物组合物，以及使用该化合物进行预防和/或治疗涉及纤维化疾病、增生性疾病、炎症性疾病、自身免疫疾病、呼吸系统疾病、心血管疾病、神经退行性疾病、皮肤病和/或与异常血管生成相关疾病的方法。
• Imaging Autotaxin <i>In Vivo</i> with ¹⁸F-Labeled Positron Emission Tomography Ligands
  作者：Xiaoyun Deng、Fernando Salgado-Polo、Tuo Shao、Zhiwei Xiao、Richard Van、Jiahui Chen、Jian Rong、Ahmed Haider、Yihan Shao、Lee Josephson、Anastassis Perrakis、Steven H. Liang

  DOI：10.1021/acs.jmedchem.1c00913

  日期：2021.10.28

  fluorinated imidazo[1,2-a]pyridine derivatives, determined their inhibition constants, and confirmed their binding mode by crystallographic analysis. Based on their promising in vitro properties, compounds 9c, 9f, 9h, and 9j were radiofluorinated. Also, a deuterated analog of [18F]9j, designated as [18F]ATX-1905 ([18F]20), was designed and proved to be highly stable against in vivo radiodefluorination compared

  自分泌运动因子 (ATX) 是一种分泌型磷酸二酯酶，与多种病理学有关，尤其是纤维化和癌症。虽然 ATX 抑制剂已进入临床领域，但目前缺乏一种经过验证的正电子发射断层扫描 (PET) 探针。为了开发合适的 ATX 靶向 PET 放射性配体，我们合成了一个聚焦的氟化咪唑并[1,2- a ]吡啶衍生物库，确定了它们的抑制常数，并通过晶体学分析确认了它们的结合模式。基于它们有希望的体外特性，化合物9c、9f、9h和9j被放射性氟化。此外，[ 18F] 9j，命名为[ 18 F]ATX-1905 ([ 18 F] 20 )，与[ 18 F] 9c , [ 18 F] 9f , [ 18 F ]相比，设计并证明对体内放射性脱氟具有高度稳定性] 9h和 [ 18 F] 9j。这些结果以及在LPS 诱导的肝损伤小鼠模型中对 ATX 的体外和体内研究表明，[ 18 F]ATX-1905 是一种适用于 ATX
• [EN] NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX COMPOSÉS COMME ANTAGONISTES DES RÉCEPTEURS A1 DE L'ADÉNOSINE
  申请人：PALOBIOFARMA SL

  公开号：WO2009044250A1

  公开（公告）日：2009-04-09

  This compounds correspond to the formula (I), where: R1 represents and aryl or heteroaryl group optionally substituted by one or more substituents selected from the group consisting of halogen atoms, straight or branched optionally substituted lower alkyl, cycloalkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, cyano, or -CO2R', wherein R' represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group; R2 represents a group selected from: a) a straight or branched lower alkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms; b) a cycloalkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms; c) a straight or branched alkylcycloalkyl or cycloalkylalkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms. Formula (I).

  这些化合物对应于公式(I)，其中：R1代表芳基或杂环基，可选择地被一个或多个取代基所取代，所述取代基从卤素原子、直链或支链的可选择取代的低烷基、环烷基、羟基、直链或支链的可选择取代的低烷氧基、氰基或-CO2R'中选择，其中R'代表氢原子或直链或支链的可选择取代的低烷基；R2代表从以下选组中选择的基团：a）被一个或多个羧基（-COOH）取代的直链或支链低烷基，可选择地被一个或多个卤素原子取代；b）被一个或多个羧基（-COOH）取代的环烷基，可选择地被一个或多个卤素原子取代；c）被一个或多个羧基（-COOH）取代的直链或支链烷基环烷基或环烷基烷基，可选择地被一个或多个卤素原子取代。公式（I）。
• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Galapagos NV

  公开号：US20170362227A1

  公开（公告）日：2017-12-21

  The present invention discloses compounds according to Formula I: Wherein R 1a , R 1b , R 2 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

  本发明揭示了符合公式I的化合物：其中，R1a，R1b，R2，R4，R5，R6a，R6b，R7，R8，W，X，Cy和下标a如本文所定义。本发明涉及抑制自体脂肪酸酰肌醇磷酸酯酶（NPP2或ENPP2）的化合物，其制备方法，包含它们的制药组合物和使用它们的治疗方法，用于预防和/或治疗涉及纤维化疾病，增生性疾病，炎症性疾病，自身免疫性疾病，呼吸系统疾病，心血管疾病，神经退行性疾病，皮肤疾病和/或异常血管生成相关疾病，通过给予本发明的化合物。